| [1] |
Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer [J]. J Clin Oncol, 2000, 18(11): 2193-2200.
|
| [2] |
de la Chapelle A. The incidence of Lynch syndrome [J]. Fam Cancer, 2005, 4(3): 233-237.
|
| [3] |
Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) [J]. N Engl J Med, 2005, 352(18): 1851-1860.
|
| [4] |
Liu B, Parsons R, Papadopoulos N, et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients [J]. Nat Med, 1996, 2(2): 169-174.
|
| [5] |
Toh JWT, Hui N, Collins G, et al. Survival outcomes associated with Lynch syndrome colorectal cancer and metachronous rate after subtotal/total versus segmental colectomy: Meta-analysis [J]. Surgery, 2022, 172(5): 1315-1322.
|
| [6] |
Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes [J]. J Clin Oncol, 2000, 18(21 Suppl): 81s-92s.
|
| [7] |
Umar A, Boland CR, Terdiman JP, et al. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability [J]. J Natl Cancer Inst, 2004, 96(4): 261-268.
|
| [8] |
Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications [J]. Clin Genet, 2009, 76(1): 1-18.
|
| [9] |
Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer [J]. J Clin Oncol, 2008, 26(35): 5783-5788.
|
| [10] |
Anyla M, Lefevre JH, Creavin B, et al. Metachronous colorectal cancer risk in Lynch syndrome patients-should the endoscopic surveillance be more intensive? [J]. Int J Colorectal Dis, 2018, 33(6): 703-708.
|
| [11] |
Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery [J]. Gut, 2011, 60(7): 950-957.
|
| [12] |
Kim TJ, Kim ER, Hong SN, et al. Survival outcome and risk of metachronous colorectal cancer after surgery in Lynch syndrome [J]. Ann Surg Oncol, 2017, 24(4): 1085-1092.
|
| [13] |
Silinskaite U, Gavelienė E, Stulpinas R, et al. A novel mutation of MSH2 gene in a patient with Lynch syndrome presenting with thirteen metachronous malignancies [J]. J Clin Med, 2023, 12(17): 5502.
|
| [14] |
Møller P, Seppälä T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database [J]. Gut, 2017, 66(3): 464-472.
|
| [15] |
Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch syndrome database [J]. Gut, 2018, 67(7): 1306-1316.
|
| [16] |
Quezada-Diaz FF, Hameed I, von Mueffling A, et al. Risk of metachronous colorectal neoplasm after a segmental colectomy in Lynch syndrome patients according to mismatch repair gene status [J]. J Am Coll Surg, 2020, 230(4): 669-675.
|
| [17] |
Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors [J]. Gastroenterology, 2014, 146(3): 643-646. e8.
|
| [18] |
Natarajan N, Watson P, Silva-Lopez E, et al. Comparison of extended colectomy and limited resection in patients with Lynch syndrome [J]. Dis Colon Rectum, 2010, 53(1): 77-82.
|
| [19] |
Fitzgibbons RJ, Jr., Lynch HT, Stanislav GV, et al. Recognition and treatment of patients with hereditary nonpolyposis colon cancer (Lynch syndromes I and II) [J]. Ann Surg, 1987, 206(3): 289-295.
|
| [20] |
Vasen HF, Mecklin JP, Watson P, et al. Surveillance in hereditary nonpolyposis colorectal cancer: an international cooperative study of 165 families. The International Collaborative Group on HNPCC [J]. Dis Colon Rectum, 1993, 36(1): 1-4.
|
| [21] |
Kalady MF, McGannon E, Vogel JD, et al. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria [J]. Ann Surg, 2010, 252(3): 507-511; discussion 511-503.
|
| [22] |
de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect [J]. Gut, 2003, 52(12): 1752-1755.
|
| [23] |
Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients [J]. Ann Surg, 2013, 257(4): 679-685.
|
| [24] |
You YN, Chua HK, Nelson H, et al. Segmental vs. extended colectomy: measurable differences in morbidity, function, and quality of life [J]. Dis Colon Rectum, 2008, 51(7): 1036-1043.
|
| [25] |
Win AK, Parry S, Parry B, et al. Risk of metachronous colon cancer following surgery for rectal cancer in mismatch repair gene mutation carriers [J]. Ann Surg Oncol, 2013, 20(6): 1829-1836.
|
| [26] |
Cirillo L, Urso ED, Parrinello G, et al. High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria [J]. Ann Surg, 2013, 257(5): 900-904.
|
| [27] |
Lee JS, Petrelli NJ, Rodriguez-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer [J]. Am J Surg, 2001, 181(3): 207-210.
|
| [28] |
O'Connell PR, Pemberton JH, Weiland LH, et al. Does rectal mucosa regenerate after ileoanal anastomosis? [J]. Dis Colon Rectum, 1987, 30(1): 1-5.
|
| [29] |
Kalady MF, Lipman J, McGannon E, et al. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer [J]. Ann Surg, 2012, 255(6): 1121-1125.
|
| [30] |
Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP, et al. Quality of life after surgery for colon cancer in patients with Lynch syndrome: partial versus subtotal colectomy [J]. Dis Colon Rectum, 2012, 55(6): 653-659.
|
| [31] |
Herzig DO, Buie WD, Weiser MR, et al. Clinical practice guidelines for the surgical treatment of patients with Lynch syndrome [J]. Dis Colon Rectum, 2017, 60(2): 137-143.
|
| [32] |
Stjepanovic N, Moreira L, Carneiro F, et al. Hereditary gastrointestinal cancers: ESMO clinical practice guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2019, 30(10): 1558-1571.
|
| [33] |
Tomita N, Ishida H, Tanakaya K, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2020 for the clinical practice of hereditary colorectal cancer [J]. Int J Clin Oncol, 2021, 26(8): 1353-1419.
|
| [34] |
Weiss JM, Gupta S, Burke CA, et al. NCCN guidelines® insights: genetic/familial high-risk assessment: colorectal, version 1.2021 [J]. J Natl Compr Canc Netw, 2021, 19(10): 1122-1132.
|
| [35] |
Renkonen-Sinisalo L, Seppälä TT, Järvinen HJ, et al. Subtotal colectomy for colon cancer reduces the need for subsequent surgery in Lynch syndrome [J]. Dis Colon Rectum, 2017, 60(8): 792-799.
|
| [36] |
Sun J, Dong M, Xiao X. Efficacy, functional outcome and postoperative complications of total abdominal colectomy with ileorectal anastomosis vs. segmental colectomy in hereditary nonpolyposis colorectal cancer [J]. Exp Ther Med, 2018, 16(3): 1603-1612.
|
| [37] |
Mork M, Hubosky SG, Roupret M, et al. Lynch syndrome: aprimer for urologists and panel recommendations [J]. J Urol, 2015, 194(1): 21-29.
|
| [38] |
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency [J]. N Engl J Med, 2015, 372(26): 2509-2520.
|
| [39] |
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [J]. Science, 2017, 357(6349): 409-413.
|
| [40] |
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer [J]. J Clin Oncol, 2018, 36(8): 773-779.
|
| [41] |
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer [J]. N Engl J Med, 2020, 383(23): 2207-2218.
|
| [42] |
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study [J]. Lancet Oncol, 2017, 18(9): 1182-1191.
|
| [43] |
Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study [J]. J Clin Oncol, 2022, 40(2): 161-170.
|
| [44] |
Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors [J]. J Hematol Oncol, 2021, 14(1): 95.
|
| [45] |
Liu DX, Li DD, He W, et al. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer [J]. Oncoimmunology, 2020, 9(1): 1711650.
|
| [46] |
Zhang C, Li D, Xiao B, et al. B2M and JAK1/2-mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy [J]. J Immunother, 2022, 45(4): 187-193.
|
| [47] |
Wang QX, Qu CH, Gao YH, et al. The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers [J]. Exp Hematol Oncol, 2021, 10(1): 2.
|
| [48] |
Botma A, Vasen HF, van Duijnhoven FJ, et al. Dietary patterns and colorectal adenomas in Lynch syndrome: the GEOLynch cohort study [J]. Cancer, 2013, 119(3): 512-521.
|
| [49] |
Winkels RM, Botma A, Van Duijnhoven FJ, et al. Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome [J]. Gastroenterology, 2012, 142(2): 241-247.
|
| [50] |
Botma A, Nagengast FM, Braem MG, et al. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study [J]. J Clin Oncol, 2010, 28(28): 4346-4353.
|
| [51] |
Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer [J]. Gastroenterology, 2000, 118(5): 829-834.
|
| [52] |
Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts [J]. Gut, 2013, 62(6): 812-823.
|
| [53] |
Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer [J]. Am J Gastroenterol, 2014, 109(8): 1159-1179.
|
| [54] |
Mathers JC, Movahedi M, Macrae F, et al. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial [J]. The Lancet Oncology, 2012, 13(12): 1242-1249.
|
| [55] |
Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial [J]. The Lancet, 2011, 378(9809): 2081-2087.
|
| [56] |
Serrano D, Patrignani P, Stigliano V, et al. Aspirin colorectal cancer prevention in Lynch syndrome: recommendations in the era of precision medicine [J]. Genes (Basel), 2022, 13(3): 460.
|
| [57] |
Burn J, Mathers JC, Bishop DT. Chemoprevention in Lynch syndrome [J]. Fam Cancer, 2013, 12(4): 707-718.
|
| [58] |
Hernandez-Sanchez A, Grossman M, Yeung K, et al. Vaccines for immunoprevention of DNA mismatch repair deficient cancers [J]. Journal for ImmunoTherapy of Cancer, 2022, 10(6): e004416.
|
| [59] |
Kloor M, Reuschenbach M, Pauligk C, et al. A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: aphase I/IIa clinical trial [J]. Clin Cancer Res, 2020, 26(17): 4503-4510.
|